• LAST PRICE
    6.9100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    7.0000/ 1
  • Ask / Lots
    7.0400/ 10
  • Open / Previous Close
    --- / 6.9100
  • Day Range
    ---
  • 52 Week Range
    Low 5.0100
    High 12.7500
  • Volume
    261
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.83
TimeVolumeCMPS
09:32 ET35136.87
09:38 ET150006.87
09:39 ET6006.94
09:41 ET3006.95
09:43 ET2006.9215
09:45 ET10506.94
09:48 ET8446.95
09:50 ET216596.985
09:52 ET1006.97
09:54 ET32176.96
09:56 ET3006.97
09:57 ET13196.965
09:59 ET5006.97
10:01 ET4006.95
10:03 ET8506.94
10:06 ET3006.94
10:08 ET16016.9
10:10 ET8456.9
10:12 ET15506.9
10:15 ET26316.94
10:17 ET3006.94
10:21 ET3616.92
10:24 ET4006.91
10:26 ET15006.9034
10:28 ET2006.89
10:30 ET22516.86
10:32 ET1486.88
10:35 ET1006.885
10:37 ET3006.87
10:39 ET10006.885
10:42 ET31006.895
10:44 ET1006.9
10:46 ET3506.8895
10:50 ET1006.9
10:51 ET4556.85
10:53 ET1006.88
10:57 ET2006.85
11:00 ET4006.84
11:02 ET1006.83
11:04 ET25016.83
11:11 ET2976.84
11:15 ET1006.83
11:18 ET3006.85
11:20 ET1006.83
11:22 ET1006.86
11:24 ET4306.8301
11:27 ET1006.86
11:29 ET1006.85
11:31 ET1006.85
11:33 ET2256.86
11:36 ET3006.85
11:40 ET8656.85
11:42 ET3006.865
11:44 ET1006.865
11:45 ET4006.86
11:51 ET2006.87
11:54 ET25086.94
11:56 ET100186.99
11:58 ET19367.01
12:02 ET3007.04
12:03 ET9007.04
12:05 ET13097.06
12:07 ET7257.03
12:09 ET1007.05
12:12 ET3257.03
12:14 ET8407.02
12:18 ET37256.95
12:20 ET12036.96
12:21 ET43726.92
12:23 ET3516.9185
12:25 ET5006.9229
12:27 ET9466.924
12:30 ET6786.9
12:34 ET1006.92
12:38 ET1006.91
12:41 ET2006.9397
12:43 ET1006.95
12:45 ET1666.94
12:50 ET7006.9425
12:52 ET4906.93
12:56 ET1006.925
01:03 ET1006.9
01:06 ET7006.93
01:14 ET2006.89
01:15 ET4986.8801
01:17 ET1506.89
01:19 ET1006.9
01:21 ET33006.86
01:24 ET3006.8861
01:26 ET32006.87
01:28 ET4006.87
01:30 ET1006.87
01:32 ET1006.87
01:35 ET1416.88
01:37 ET6326.88
01:39 ET1006.88
01:42 ET1006.88
01:44 ET1006.87
01:50 ET1096.86
01:55 ET11356.879
02:00 ET1006.88
02:02 ET2006.88
02:06 ET2006.88
02:11 ET7126.86
02:13 ET1006.86
02:15 ET9006.8898
02:22 ET1006.8819
02:24 ET1006.88
02:27 ET3086.895
02:29 ET1006.9
02:31 ET4006.88
02:33 ET5006.87
02:36 ET1506.889
02:38 ET8006.89
02:45 ET4006.8818
02:49 ET2006.88
02:54 ET3406.87
03:02 ET11116.87
03:12 ET2006.875
03:14 ET2006.9099
03:18 ET11246.895
03:20 ET2006.88
03:21 ET1006.88
03:25 ET1006.88
03:30 ET1506.895
03:32 ET1006.9
03:34 ET2006.88
03:38 ET3996.866
03:41 ET2176.89
03:43 ET5376.896
03:45 ET7006.8818
03:48 ET4196.9
03:50 ET2006.891
03:52 ET8006.88
03:54 ET13006.8899
03:56 ET14676.89
03:57 ET9406.89
03:59 ET156446.91
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCMPS
Compass Pathways PLC
472.6M
-3.0x
---
United StatesMNMD
Mind Medicine (MindMed) Inc
473.8M
-2.6x
---
United StatesAVXL
Anavex Life Sciences Corp
480.8M
-11.3x
---
United StatesALT
Altimmune Inc
484.0M
-4.2x
---
United StatesSLRN
ACELYRIN Inc
487.1M
-1.6x
---
United StatesAURA
Aura Biosciences Inc
447.0M
-5.0x
---
As of 2024-09-27

Company Information

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Contact Information

Headquarters
3Rd Floor, 1 Ashley RoadALTRINCHAM, United Kingdom WA14 2DT
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Gino Santini
Chief Executive Officer, Executive Director
Kabir Nath
Chief Financial Officer
Teri Loxam
General Counsel, Chief Legal Officer
Matthew Owens
Chief Commercial Officer
Lori Englebert

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$472.6M
Revenue (TTM)
$0.00
Shares Outstanding
68.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.27
EPS
$-2.30
Book Value
$3.64
P/E Ratio
-3.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.